Alemtuzumab in Multiple Sclerosis: Lessons from Social Media in Enhancing Patient Care

BACKGROUND: Alemtuzumab is a monoclonal antibody that has been approved for the treatment of relapsing-remitting multiple sclerosis (MS). Alemtuzumab is associated with infusion reactions and potential autoimmune complications. Patient education and understanding are crucial to favorable outcomes. O...

Полное описание

Сохранить в:
Библиографические подробности
Опубликовано в: :Int J MS Care
Главные авторы: Rath, Louise, Vijiaratnam, Nirosen, Skibina, Olga
Формат: Artigo
Язык:Inglês
Опубликовано: The Consortium of Multiple Sclerosis Centers 2017
Предметы:
CME/CNE Article • 2017 Series • Number 6
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC5734716/
https://ncbi.nlm.nih.gov/pubmed/29270090
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.7224/1537-2073.2017-010
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы